Browsing Tag
oncology research
12 posts
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position…
AstraZeneca’s CALQUENCE demonstrates enhanced efficacy in mantle cell lymphoma trial
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE…
Dizal’s sunvozertinib shows promising results in global pivotal lung cancer study
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from…
Datopotamab deruxtecan shows promise in Phase III trial for NSCLC
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential…
Theratechnologies to unveil promising long-term efficacy for sudocetaxel zendusortide in solid tumors at ASCO 2024
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical leader focused on innovative therapy developments, has revealed Phase 1…
Novartis to expand oncology portfolio with acquisition of Mariana Oncology
Novartis has announced a significant move in the oncology sector with its agreement to acquire Mariana Oncology, a…
AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Truqap (capivasertib) in…
MaaT Pharma commences HERACLES Phase 2 trial for MaaT013 in battle against acute graft-versus-host disease
MaaT Pharma, a French oncology company, has announced a significant milestone in its clinical research: the dosing of…
Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors
Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining…
AstraZeneca secures FDA approval for Lumoxiti in hairy cell leukemia treatment
AstraZeneca has achieved a major regulatory milestone with the US Food and Drug Administration (FDA) approval of Lumoxiti…